ClinicalTrials.gg
CompletedNCT00844597Updated Oct 6, 2015Results posted

Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients

A Phase 1/2 interventional study of AVI-4658 for Injection in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 2 sites in United Kingdom. Open to male participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2015-10-06.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
5 Years to 15 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.

Enrollment
5th of 11
19 · median 15
Started
2009
the only one that year
Phase 1/2
2 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
9 of 11
Sarepta Therapeutics, Inc.

Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 5th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 1/2, and was the 2nd registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About eteplirsen

eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 5 Years to 15 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne as a file.
02

Study summary

The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO).

Read the detailed description

Primary outcome is safety, tolerability and dose selection for future studies.

03

Conditions studied

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
5 Years to 15 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has provided written informed assent (as required by EC) and parents/guardians have provided written .
  2. Has an out-of-frame deletion(s) that could be corrected by skipping exon 51 based on DNA sequencing data from the candidate.
  3. Is male and between the ages of ≥ 5 years and ≤ 15 years.
  4. Has a muscle analysis showing \< 5% revertant fibres present at baseline.
  5. DNA sequencing of the candidate's dystrophin exon 51 confirms that no DNA polymorphisms are present that could compromise PMO duplex formation or there is confirmation of in vitro dystrophin production after AVI-4658 exposure to fibroblast or myoblast in vitro cultures.
  6. Intact right and left bicep muscles or alternative arm muscle group.
  7. Is able to walk independently at least 25 meters.
  8. Has a forced vital capacity (FVC) ≥ 50% of predicted and does not require ventilatory support or supplemental oxygen.
  9. Receives the standard of care for DMD as recommended by the DMD care recommendations from the North Star UK and TREAT-NMD.
  10. The parent(s) or legal guardian and Subject have undergone counselling about the expectations of this protocol and agree to participate.
  11. The parent(s) or legal guardian and Subject intend to comply with all study evaluations and return for all study activities.

Exclusion criteria

Exclusion Criteria:

  1. A DNA polymorphism within exon 51 that may compromise PMO duplex formation.
  2. Known antibodies to dystrophin.
  3. Lacks intact right and left bicep muscles or alternative arm muscle group.
  4. A calculated less than 70% of predicted normal for age based on the Cockcroft and Gault Formula.
  5. A (EF) of \< 35% and/or fractional shortening of \<25% based on echocardiography (ECHO)during screening.
  6. A history of respiratory insufficiency as defined by need for intermittent or continuous supplemental oxygen.
  7. A severe cognitive dysfunction rendering the potential subject unable to understand and comply with the study protocol.
  8. Any known immune deficiency or disease.
  9. A known bleeding disorder or has received chronic anticoagulant treatment within three months of study entry.
  10. Receipt of pharmacologic treatment, apart from , that might affect muscle strength or function within 8 weeks of study entry (viz., growth hormone, anabolic steroids).
  11. Surgery within 3 months of study entry or planned for anytime during the duration of the study.
  12. Another illness at time of study entry.
  13. Subject or parent has active psychiatric disorder, has adverse psychosocial circumstances,recent significant emotional loss, and/or history of depressive or anxiety disorder that might interfere with protocol compliance.
  14. Use of any experimental treatments, has participated in any DMD interventional clinical trial within 4 weeks of study entry or participated in the AVI-4658-33 intramuscular (i.m.) trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Cohort 1 - 0.5 mg/kg/wk

    Subjects in this group will receive a 0.5 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period

    Drug: AVI-4658 for Injection

  • Experimental
    Cohort 2 - 1.0 mg/kg/wk

    Subjects in this group will receive a 1.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period

    Drug: AVI-4658 for Injection

  • Experimental
    Cohort 3 - 2.0 mg/kg/wk

    Subjects in this group will receive a 2.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period

    Drug: AVI-4658 for Injection

  • Experimental
    Cohort 4 - 4.0 mg/kg/wk

    Subjects in this group will receive a 4.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period

    Drug: AVI-4658 for Injection

  • Experimental
    Cohort 5 - 10.0 mg/kg/wk

    Subjects in this group will receive a 10.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period

    Drug: AVI-4658 for Injection

  • Experimental
    Cohort 6 - 20.0 mg/kg/wk

    Subjects in this group will receive a 20.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period

    Drug: AVI-4658 for Injection

Interventions

  • DrugEteplirsenStudies of EteplirsenEteplirsen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.

    Also known as: Eteplirsen

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Number of subjects with 1 or more Treatment Emergent Adverse Event that are possibly related to the investigational drug

    Time frame: Baseline to 6 months

  2. Treatment Emergent Adverse Events

    Number of Patients with Treatment Emergent Adverse Events

    Time frame: from Baseline to Follow up (27 weeks)

Secondary outcomes

  1. Pharmacokinetics - Mean Peak Plasma Concentration of AVI-4658 After Administration

    Standard Pharmacokinetic parameters estimated using non-compartmental modeling of plasma concentration data.

    Time frame: Samples were taken: 30 minutes pre dose; and at 5 (±1), 15 (±2), 30 (±5), 60 (±5), and 90 (±5) minutes; and 2, 4, 6, 8, 12, and 24 hours (all ± 15 minutes) post dose at Weeks 1, 6, and 12

  2. Efficacy of Eteplirsen Over 12 Weeks of Dosing

    Efficacy was defined as an estimated change in the percentage of dystrophin positive fibers (assessed by IHC) at Week 14 from Baseline after 12 weekly doses of eterplirsen. This outcome measure represents the number of patients to show an increase in the percentage of dystrophin-positive fibers.

    Time frame: Biopsies were taken at Baseline and Week 14

07

Results

Posted Oct 6, 2015
Limitations and caveats
Due to the small number of study participants, a single adverse event (AE) in 1 patient exceeds the reporting threshold of 5%. Refer to the "Post-Hoc Outcome Measures" #5 for a summary of frequent and related AEs.

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 - 0.5 mg/kg/wkCohort 2 - 1.0 mg/kg/wkCohort 3 - 2.0 mg/kg/wkCohort 4 - 4.0 mg/kg/wkCohort 5 - 10.0 mg/kg/wkCohort 6 - 20.0 mg/kg/wk
Started422344
Completed422244
Not completed000100
Withdrew: Adverse event000100

Outcome measures

PrimarySafety and Tolerability

Number of subjects with 1 or more Treatment Emergent Adverse Event that are possibly related to the investigational drug

Time frame:
Baseline to 6 months
Reported as:
Number · participants
Safety and Tolerability
participantsOpen Label Treatment Arm
Safety and Tolerability14
SecondaryPharmacokinetics - Mean Peak Plasma Concentration of AVI-4658 After Administration

Standard Pharmacokinetic parameters estimated using non-compartmental modeling of plasma concentration data.

Time frame:
Samples were taken: 30 minutes pre dose; and at 5 (±1), 15 (±2), 30 (±5), 60 (±5), and 90 (±5) minutes; and 2, 4, 6, 8, 12, and 24 hours (all ± 15 minutes) post dose at Weeks 1, 6, and 12
Reported as:
Mean · ng/mL
Pharmacokinetics - Mean Peak Plasma Concentration of AVI-4658 After Administration
ng/mLOpen Label Treatment Arm
Pharmacokinetics - Mean Peak Plasma Concentration of AVI-4658 After Administration39000 ± 16900
SecondaryEfficacy of Eteplirsen Over 12 Weeks of Dosing

Efficacy was defined as an estimated change in the percentage of dystrophin positive fibers (assessed by IHC) at Week 14 from Baseline after 12 weekly doses of eterplirsen. This outcome measure represents the number of patients to show an increase in the percentage of dystrophin-positive fibers.

Time frame:
Biopsies were taken at Baseline and Week 14
Reported as:
Number · participants
Efficacy of Eteplirsen Over 12 Weeks of Dosing
participantsOpen Label Treatment Arm
Efficacy of Eteplirsen Over 12 Weeks of Dosing11
PrimaryTreatment Emergent Adverse Events

Number of Patients with Treatment Emergent Adverse Events

Time frame:
from Baseline to Follow up (27 weeks)
Reported as:
Number · participants
Treatment Emergent Adverse Events
participantsOpen Label Treatment Arm
Treatment Emergent Adverse Events19
Post-hocAdverse Events >15%

Adverse events that occurred in \>15% of overall patient population across dose level arms.

Time frame:
27 Weeks
Reported as:
Number · Events
Adverse Events >15%
EventsCohort 1 - 0.5 mg/kg/wkCohort 2 - 1.0 mg/kg/wkCohort 3 - 2.0 mg/kg/wkCohort 4 - 4.0 mg/kg/wkCohort 5 - 10.0 mg/kg/wkCohort 6 - 20.0 mg/kg/wk
Cardiomyopathy000102
Tachycardia000102
Abdominal Pain010110
Nausea001101
Vomiting001110
Influenza like illness002010
Rhinitis100141
Upper respiratory tract infection210122
Fall200201
Arthralgia101100
Back Pain101221
Myalgia111010
Dizziness001101
Headache212021

Adverse events

Collected over Adverse Event data for this study was collected from Baseline to Follow-up (27 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - 0.5 mg/kg/wk—0/4 (0%)4/4 (100%)
Cohort 2 - 1.0 mg/kg/wk—0/2 (0%)2/2 (100%)
Cohort 3 - 2.0 mg/kg/wk—1/2 (50%)2/2 (100%)
Cohort 4 - 4.0 mg/kg/wk—1/3 (33.3%)3/3 (100%)
Cohort 5 - 10.0 mg/kg/wk—0/4 (0%)4/4 (100%)
Cohort 6 - 20.0 mg/kg/wk—0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1 - 0.5 mg/kg/wkCohort 2 - 1.0 mg/kg/wkCohort 3 - 2.0 mg/kg/wkCohort 4 - 4.0 mg/kg/wkCohort 5 - 10.0 mg/kg/wkCohort 6 - 20.0 mg/kg/wk
Post-Operative Nausea and VomitingGastrointestinal disorders0/40/21/20/30/40/4
Fracture of Left Medial MalleolusMusculoskeletal and connective tissue disorders0/40/20/21/30/40/4
Most frequent other events
Showing 10 of 63
Most frequent other events
EventCohort 1 - 0.5 mg/kg/wkCohort 2 - 1.0 mg/kg/wkCohort 3 - 2.0 mg/kg/wkCohort 4 - 4.0 mg/kg/wkCohort 5 - 10.0 mg/kg/wkCohort 6 - 20.0 mg/kg/wk
RhinitisInfections and infestations1/40/20/21/34/41/4
HeadacheNervous system disorders2/41/22/20/32/41/4
Influenza like illnessGeneral disorders0/40/22/20/31/40/4
FallInjury, poisoning and procedural complications2/40/20/22/30/41/4
Back painMusculoskeletal and connective tissue disorders1/40/21/22/32/41/4
Upper respiratory tract infectionInfections and infestations2/41/20/21/32/42/4
MyalgiaMusculoskeletal and connective tissue disorders1/41/21/20/31/40/4
TachycardiaCardiac disorders0/40/20/21/30/42/4
NauseaGastrointestinal disorders0/40/21/21/30/41/4
VomitingGastrointestinal disorders0/40/21/21/31/40/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1 - 0.5mg/kg/wkCohort 2 - 1.0mg/kg/wkCohort 3 - 2.0mg/kg/wkCohort 4 - 4.0mg/kg/wkCohort 5 - 10.0mg/kg/wkCohort 6 - 20.0mg/kg/wkTotal
Mean8.3 ± 0.506.0 ± 0.011.0 ± 2.839.7 ± 0.588.8 ± 2.758.8 ± 1.268.7 ± 1.91
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - 0.5mg/kg/wkCohort 2 - 1.0mg/kg/wkCohort 3 - 2.0mg/kg/wkCohort 4 - 4.0mg/kg/wkCohort 5 - 10.0mg/kg/wkCohort 6 - 20.0mg/kg/wkTotal
Female0000000
Male42234419
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 - 0.5mg/kg/wkCohort 2 - 1.0mg/kg/wkCohort 3 - 2.0mg/kg/wkCohort 4 - 4.0mg/kg/wkCohort 5 - 10.0mg/kg/wkCohort 6 - 20.0mg/kg/wkTotal
Hispanic or Latino0000000
Not Hispanic or Latino42234419
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 - 0.5mg/kg/wkCohort 2 - 1.0mg/kg/wkCohort 3 - 2.0mg/kg/wkCohort 4 - 4.0mg/kg/wkCohort 5 - 10.0mg/kg/wkCohort 6 - 20.0mg/kg/wkTotal
American Indian or Alaska Native0000000
Asian0100001
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White41234418
More than one race0000000
Unknown or Not Reported0000000
Body Weight
Body Weight(kilograms)Cohort 1 - 0.5mg/kg/wkCohort 2 - 1.0mg/kg/wkCohort 3 - 2.0mg/kg/wkCohort 4 - 4.0mg/kg/wkCohort 5 - 10.0mg/kg/wkCohort 6 - 20.0mg/kg/wkTotal
Mean33 ± 4.0923.7 ± 3.4642.6 ± 6.3640.1 ± 19.0034.6 ± 14.0133.0 ± 8.7134.5 ± 10.84
Height
Height(centimeters)Cohort 1 - 0.5mg/kg/wkCohort 2 - 1.0mg/kg/wkCohort 3 - 2.0mg/kg/wkCohort 4 - 4.0mg/kg/wkCohort 5 - 10.0mg/kg/wkCohort 6 - 20.0mg/kg/wkTotal
Mean127.3 ± 5.05110.7 ± 4.45126.9 ± 5.09126.9 ± 14.40123.7 ± 10.04126.5 ± 7.18124.5 ± 8.99
08

Study locations

2 sites
  • Great Ormond Street Hospital
    London, England WC1N 3JH, United Kingdom
  • Royal Victoria Infirmary
    Newcastle Upon Tyne, England NE2 4LP, United Kingdom
09

References and documents

Publications

  • Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011 Aug 13;378(9791):595-605. doi: 10.1016/S0140-6736(11)60756-3. Epub 2011 Jul 23. PubMed 21784508 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jun 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2008
First posted
Feb 16, 2009
Start
Jan 2009
Primary completionActual
Jun 2010
CompletionActual
Dec 2010
Results first posted
Oct 6, 2015
Last update
Oct 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00844597
Collaborators
British Medical Research Council
Responsible party
Sponsor
First posted
Feb 16, 2009
Start date
Jan 2009
Primary completion
Jun 2010
Completion
Dec 2010
Results posted
Oct 6, 2015
Last update
Oct 6, 2015

Study contacts

Austen Eddy, MSM
study director · AVI BioPharma, Director, Clinical Operations

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eteplirsen

Start the discussion